ImmuCell

OverviewSuggest Edit

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. ImmuCell has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

... Show more
TypePublic
Founded1982
HQPortland, USMap
Websiteimmucell.com
Employee Ratings3More

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2018)25(+79%)
Share Price (Feb 2019)$7.9 (+6%)

Key People/Management at ImmuCell

Elizabeth L. Williams

Elizabeth L. Williams

Vice President of Manufacturing Operations
David S. Cunningham

David S. Cunningham

Director
Jonathan E. Rothschild

Jonathan E. Rothschild

Director
Show more

ImmuCell Office Locations

ImmuCell has an office in Portland
Portland, US (HQ)
56 Evergreen Dr
Show all (1)
Report incorrect company information

ImmuCell Financials and Metrics

ImmuCell Revenue

USD

Net income (Q3, 2018)

(250.0k)

Market capitalization (12-Feb-2019)

43.3m

Closing stock price (12-Feb-2019)

7.9

Cash (30-Sep-2018)

2.4m
ImmuCell's current market capitalization is $43.3 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cost of goods sold

2.9m4.0m4.1m5.2m

Sales and marketing expense

986.8k1.6m1.8m1.9m

Operating expense total

986.8k1.6m1.8m1.9m

EBIT

2.1m890.2k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cost of goods sold

619.0k931.9k661.2k692.2k829.8k860.5k1.2m1.1m763.5k1.4m828.3k1.1m1.5m1.5m1.2m

Sales and marketing expense

258.2k285.3k262.7k373.6k316.3k381.7k419.0k462.3k483.7k514.5k400.4k446.7k531.9k475.2k494.7k

Operating expense total

258.2k285.3k262.7k373.6k316.3k381.7k419.0k462.3k483.7k514.5k400.4k446.7k531.9k1.0m494.7k

EBIT

12.6k40.9k214.0k626.9k699.0k21.5k50.5k918.2k
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.3m850.0k1.6m5.2m3.8m

Accounts Receivable

631.4k1.0m754.1k992.4k1.3m

Inventories

1.2m945.8k870.2k2.1m2.0m

Current Assets

7.3m5.5m7.9m14.3m7.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

2.9m2.2m1.7m1.2m1.9m2.5m4.6m3.7m4.4m4.3m3.8m2.3m3.1m2.5m2.4m

Accounts Receivable

720.0k428.4k563.6k735.0k789.2k1.5m947.3k677.2k1.0m705.0k868.9k999.9k985.2k854.0k

Inventories

1.5m947.3k944.2k1.0m646.1k864.4k980.9k1.2m1.8m2.1m2.6m2.7m1.9m1.8m2.2m

Current Assets

7.7m6.8m6.3m6.1m5.6m8.2m13.2m13.0m12.7m10.9m8.0m6.3m6.4m5.8m6.2m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

117.4k(167.2k)1.2m508.4k(168.1k)

Depreciation and Amortization

417.2k446.0k529.3k802.4k904.4k

Inventories

442.5k260.8k75.5k(1.1m)77.2k

Accounts Payable

(95.5k)178.6k60.4k(182.5k)448.6k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

268.1k(13.3k)(308.1k)(297.8k)573.1k924.4k452.4k443.3k478.2k584.2k365.9k26.5k(221.1k)(1.0m)(1.3m)

Depreciation and Amortization

295.3k113.1k228.7k333.0k245.2k380.5k173.2k387.6k590.8k218.2k430.7k641.5k284.7k570.1k952.7k

Inventories

158.5k259.2k262.3k167.1k299.6k81.3k2.3k(245.7k)(783.2k)28.0k(488.8k)(605.1k)119.8k212.8k(200.2k)

Accounts Payable

(130.5k)22.0k15.4k4.8k(157.1k)(92.3k)(167.1k)(190.4k)(100.7k)128.1k5.6k262.3k(214.8k)(299.4k)(58.5k)
show all
USDY, 2018

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Competitors

Cannabis Sativa
Healthcare - Public
CTD Holdings
Healthcare - Public
Enanta Pharmaceuticals
Healthcare - Public
Endologix
Healthcare - Public
Compare competitors

ImmuCell News and Updates

February 13, 2019

ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018

PORTLAND, Maine, Feb. 13, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cat…
February 06, 2019

ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018

Conference Call Scheduled for Thursday, February 14, 2019 at 9:00 AM ET Conference Call Scheduled for Thursday, February 14, 2019 at 9:00 AM ET
Report incorrect company information

ImmuCell Company Life and Culture

Report incorrect company information

 ImmuCell Frequently Asked Questions

  • When was ImmuCell founded?

    ImmuCell was founded in 1982.

  • Who are ImmuCell key executives?

    ImmuCell's key executives are Elizabeth L. Williams, David S. Cunningham and Jonathan E. Rothschild.

  • How many employees does ImmuCell have?

    ImmuCell has 25 employees.

  • Who are ImmuCell competitors?

    Competitors of ImmuCell include Cannabis Sativa, CTD Holdings and Enanta Pharmaceuticals.

  • Where is ImmuCell headquarters?

    ImmuCell headquarters is located at 56 Evergreen Dr, Portland.

  • Where are ImmuCell offices?

    ImmuCell has an office in Portland.

  • How many offices does ImmuCell have?

    ImmuCell has 1 office.